1. SU11. Amisulpride Augmentation of Clozapine for Treatment-Refractory Schizophrenia: The AMICUS Study
- Author
-
Rameez Zafar, Khalid Iqbal, Leeson, T Amos, Raj Kumar, Louise Marston, Peter M. Haddad, Pavel Fridrich, Carol Paton, Patrick Keown, Hemant Bagalkote, Singh, Thomas R. E. Barnes, David Osborn, Zachary Fitzgerald, and Mariwan Husni
- Subjects
medicine.medical_specialty ,Psychotherapist ,Positive and Negative Syndrome Scale ,Treatment refractory ,medicine.disease ,03 medical and health sciences ,Psychiatry and Mental health ,Abstracts ,0302 clinical medicine ,Pharmacotherapy ,Schizophrenia ,030220 oncology & carcinogenesis ,medicine ,Amisulpride ,Psychiatry ,Psychology ,030217 neurology & neurosurgery ,Clozapine ,medicine.drug - Abstract
Background: In around a third of people with schizophrenia, the illness responds poorly to standard treatment with antipsychotic medication. Clozapine is the only antipsychotic medication with robust evidence for efficacy in strictly defined treatment-resistant schizophrenia, but even then, an adequate response is seen in only 30%–60% of patients. When a trial of clozapine proves to be insufficient, clinicians commonly add a second antipsychotic, although robust evidence to justify this practice, with regard to the potential benefits and risks, is lacking.
- Published
- 2017